Nortriptyline-fluvoxamine

From Psychiatrienet
Revision as of 14:08, 2 November 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Nortriptyline
Type Antidepressant
Group TCA
links
Medscape Nortriptyline
PubChem 4543
PubMed Nortriptyline
Kompas (Dutch) Nortriptyline
Wikipedia Nortriptyline
Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine

Switch medication from nortriptyline to fluvoxamine.[1] [2]

Nietinrijdenbord.png Stop nortriptyline
  • Before day 1: gradually reduce dosage of nortriptyline to a maximum of 50-100 mg/day.
  • Day 1: reduce dosage of nortriptyline to 50 mg/day.
  • Day 3: reduce dosage of nortriptyline to 25 mg/day.
Eenrichtingbord.png Start fluvoxamine
  • Day 1: simultaneously start administration of fluvoxamine in a normal dosage of 50 mg/day.
  • Day 8: stop administration of nortriptyline and continue administration of fluvoxamine in a dosage of 50-100 mg/day.
Infobord.png More information
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.